Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

The usual dose of Novo Nordisk’s expensive weight-loss drug Wegovy can be cut in half without affecting the results, ...

One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

One downside is that nearly… Receive a weekly dose of discovery in your inbox! We'll also keep you up to date with New Scientist events and special offers. Radical photon idea could rewrite ...

Thousands celebrate the rapid results of weight loss injections. But a new analysis reveals a harsh truth few are prepared ...

focusing on patients who previously discontinued Wegovy® due to tolerability issues. The trial’s pharmacokinetic results support the proposed weekly dosing, and no significant cardiovascular ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables ... a large increase in dosage will require an even ...